Treatment of Cytomegaloviral Pneumonia with High-Dose Acyclovir and Human Leukocyte Interferon

Authors:

Abstract
Thirteen recipients of bone marrow transplants were given high-dose acyclovir and α-interferon (Cantell interferon) for the treatment of biopsy-proven cytomegaloviral pneumonia. Three patients survived. Doses of acyclovir between 500 and 1,000 mg/m2 of body surface area (peak plasma levels, 7–86 μg/ml) and doses of interferon between 2 × 104 and 40 × 104 units/kg per day (peak serum levels, 5–608 units/ml) were given. No consistent antiviral effect was seen despite the large doses employed. Possible marrow toxicity associated with this regimen occurred in five patients, neurologic symptoms in two, and nephrotoxicity in one. Thus, treatment with high-dose acyclovir plus a-interferon was moderately toxic but ineffective against cytomegaloviral pneumonia after bone marrow transplantation.